MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Net income 2016–2025
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$10.3MFY2025 · since FY2016: -$7.6M → -$10.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$10.3M | +57.3% |
| FY2024 | -$24.3M | -5.7% |
| FY2023 | -$22.9M | -9.3% |
| FY2022 | -$21.0M | +9.8% |
| FY2021 | -$23.3M | -3.7% |
| FY2020 | -$22.4M | -29.2% |
| FY2019 | -$17.4M | -23.4% |
| FY2018 | -$14.1M | +9.1% |
| FY2017 | -$15.5M | -103.8% |
| FY2016 | -$7.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MTNB financial trends
MTNB RevenueMTNB Net marginMTNB Gross profitMTNB Gross marginMTNB Operating incomeMTNB Operating marginMTNB Operating cash flowMTNB Free cash flowMTNB Capital expendituresMTNB Return on equityMTNB Stock buybacksMTNB Dividends paidMTNB Total assetsMTNB Total liabilitiesMTNB Shareholders’ equityMTNB overview →